Immunic Study (Industry Sponsored) - Wesley Research Institute
Wesley Research Institute
Donate
Now

This clinical trial will investigate a potential treatment option for coeliac disease. This could potentially improve quality of life for people with coeliac disease.

Research Objectives

Status

Completed

Recruitment

Closed

Patient Group

Patients with positive coeliac disease biopsy

Study location

Wesley Research Institute

Study type

Industry Sponsored
Sponsors: Immunic Australia

Lead investigators

  • A/Prof James Daveson

Clinical Trial Coordinator

  • Emma Brownrigg

Technical title

A three-part double blind, placebo controlled Phase 1 B of IMU-856 in healthy volunteers and patients with Coeliac Disease

About this research project

This clinical trial will investigate a potential treatment option for coeliac disease. The only effective treatment currently available for coeliac disease is a strict, lifelong, gluten-free diet. With gluten being present in a variety of food and drinks, this study brings hope to people suffering with this disease. This study will assess the safety and tolerability of a potential new oral treatment (IMU-856) when given to people with coeliac disease. This treatment works by blocking a protein found in the gut, which is believed to play an important role in strengthening the delicate lining of the gut in order to prevent damage that might cause an inflammatory reaction. This could potentially improve quality of life for people with coeliac disease.

Our goals:

  • Research into faster and more accurate diagnosis
  • Improve understanding around the causes of disease and better prediction of disease progression
  • Increase survival and quality of life for patients and families

 

Latest News

Lung Cancer METASPATIAL Study awarded $1 million by the Australian Government

We’re delighted to announce that Dr Arutha Kulasinghe is leading the Lung Cancer METASPATIAL Study that has been awarded nearly $1m by the Australian Government. The project is supported by the Wesley Research Institute and the University of Queensland. The METASPATIAL Study will be undertaken over the next 4 years at Wesley Research Institute’s new Queensland Spatial Biology Centre (QSBC).

Lung Cancer Survivor Michel Itel an advocate for Spatial Mapping of Digital Pathology

As a patient with a specific EGFR positive mutation, Michel benefited from targeted therapy, an approach that the new Queensland Spatial Biology Centre (QSBC) aims to enhance for future patients.
Amanda

Amanda’s Story

Flashback to the middle of 2019, it was just like any other normal day at work for Amanda, until she noticed a lump in her groin.
1 2 3 8
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram